{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:35:16Z","timestamp":1792798516735,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10787-025-01726-w","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:50:50Z","timestamp":1744887050000},"page":"2565-2588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gut microbiota and Parkinson\u2019s Disease: a new frontier in understanding neurological health"],"prefix":"10.1007","volume":"33","author":[{"given":"Nishchhal","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeranjaneyulu","family":"Addepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7281-4716","authenticated-orcid":false,"given":"Ashwani","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-2813","authenticated-orcid":false,"given":"Meghraj","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"1726_CR1","unstructured":"\u201cAlpha-Synuclein Antibodies and Uses Thereof.\u201d 1. https:\/\/patents.google.com\/patent\/WO2014132210A1\/en#patentCitations (September 22, 2024)."},{"key":"1726_CR2","unstructured":"\u201cBioArctic Receives Patent in Japan for New Antibodies Targeting Parkinson\u2019s Disease.\u201d 4. https:\/\/www.prnewswire.com\/news-releases\/bioarctic-receives-patent-in-japan-for-new-antibodies-targeting-parkinsons-disease-301907860.html (September 22, 2024)."},{"issue":"1","key":"1726_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VTE Aho","year":"2021","unstructured":"Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L et al (2021) Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol Neurodegener 16(1):1\u201314. https:\/\/doi.org\/10.1186\/s13024-021-00427-6","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1726_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.fsi.2015.05.038","volume":"45","author":"N Akhter","year":"2015","unstructured":"Akhter N, Bin Wu, Memon AM, Mohsin M (2015) Probiotics and prebiotics associated with aquaculture: a review. Fish Shellfish Immunol 45(2):733\u2013741. https:\/\/doi.org\/10.1016\/j.fsi.2015.05.038","journal-title":"Fish Shellfish Immunol"},{"issue":"26","key":"1726_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/molecules26","volume":"2021","author":"O Anna","year":"2021","unstructured":"Anna O, Oniszczuk T, Gancarz M, Nska JS, Hamaguchi M (2021) Molecules role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. Molecules 2021(26):1172. https:\/\/doi.org\/10.3390\/molecules26","journal-title":"Molecules"},{"issue":"1","key":"1726_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/MOG.0b013e32835a4b3e","volume":"29","author":"OC Aroniadis","year":"2013","unstructured":"Aroniadis OC, Brandt LJ (2013) Fecal microbiota transplantation. Curr Opin Gastroen 29(1):79\u201384. https:\/\/doi.org\/10.1097\/MOG.0b013e32835a4b3e","journal-title":"Curr Opin Gastroen"},{"issue":"2","key":"1726_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s13668-024-00539-7","volume":"13","author":"\u015e Ayten","year":"2024","unstructured":"Ayten \u015e, Bilici S (2024) Modulation of gut microbiota through dietary intervention in neuroinflammation and Alzheimer\u2019s and Parkinson\u2019s Diseases. Curr Nutr Rep 13(2):82\u201396. https:\/\/doi.org\/10.1007\/s13668-024-00539-7","journal-title":"Curr Nutr Rep"},{"key":"1726_CR8","doi-asserted-by":"publisher","first-page":"1386608","DOI":"10.3389\/fneur.2024.1386608","volume":"15","author":"R Bhidayasiri","year":"2024","unstructured":"Bhidayasiri R, Sringean J, Phumphid S, Anan C, Thanawattano C, Deoisres S et al (2024) The rise of Parkinson\u2019s disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and \u201ceat, move, sleep\u201d lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand. Front Neurol 15:1386608","journal-title":"Front Neurol"},{"issue":"1","key":"1726_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/jpm12010049","volume":"12","author":"B Bicknell","year":"2022","unstructured":"Bicknell B, Liebert A, McLachlan CS, Kiat H (2022) Microbiome changes in humans with Parkinson\u2019s Disease after photobiomodulation therapy: a retrospective study. J Pers Med 12(1):49. https:\/\/doi.org\/10.3390\/jpm12010049","journal-title":"J Pers Med"},{"issue":"1","key":"1726_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/jpm14010112","volume":"14","author":"B Bicknell","year":"2024","unstructured":"Bicknell B, Liebert A, Herkes G (2024) Parkinson\u2019s disease and photobiomodulation: potential for treatment. J Pers Med 14(1):112. https:\/\/doi.org\/10.3390\/jpm14010112","journal-title":"J Pers Med"},{"issue":"4","key":"1726_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/microorganisms12040634","volume":"12","author":"S Binda","year":"2024","unstructured":"Binda S, Tremblay A, Iqbal UH, Kassem O, Le Barz M, Thomas V, Bronner S et al (2024) Psychobiotics and the microbiota\u2013gut\u2013brain axis: where do we go from here? Microorganisms 12(4):634. https:\/\/doi.org\/10.3390\/microorganisms12040634","journal-title":"Microorganisms"},{"issue":"2","key":"1726_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11065-022-09540-9","volume":"33","author":"M Bucur","year":"2023","unstructured":"Bucur M, Papagno C (2023) Deep brain stimulation in Parkinson\u2019s Disease: a meta-analysis of the long-term neuropsychological outcomes. Neuropsychol Rev 33(2):307\u2013346. https:\/\/doi.org\/10.1007\/s11065-022-09540-9","journal-title":"Neuropsychol Rev"},{"issue":"9","key":"1726_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson\u2019s Disease: efficacy and safety of current and new formulations. CNS Drugs 33(9):905\u2013918. https:\/\/doi.org\/10.1007\/s40263-019-00661-z","journal-title":"CNS Drugs"},{"issue":"5","key":"1726_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4274\/balkanmedj.galenos.2022.2022-7-100","volume":"39","author":"E \u00c7\u0131nar","year":"2022","unstructured":"\u00c7\u0131nar E, Tel BC, \u015eahin G (2022) Neuroinflammation in Parkinson\"s Disease and its treatment opportunities. Balkan Med J 39(5):318\u2013333. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2022.2022-7-100","journal-title":"Balkan Med J"},{"issue":"6","key":"1726_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/00003088-199630060-00004","volume":"30","author":"M Contin","year":"1996","unstructured":"Contin M, Riva R, Albani F, Baruzzi A (1996) Pharmacokinetic optimisation in the treatment of Parkinson\u2019s Disease. Clin Pharmacokinet 30(6):463\u2013481. https:\/\/doi.org\/10.2165\/00003088-199630060-00004","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1726_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Maral Mouradian M (2013) The role of oxidative stress in Parkinson\u2019s Disease. JPD 3(4):461\u2013491. https:\/\/doi.org\/10.3233\/JPD-130230","journal-title":"JPD"},{"issue":"10","key":"1726_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.biopsych.2013.05.001","volume":"74","author":"TG Dinan","year":"2013","unstructured":"Dinan TG, Stanton C, Cryan JF (2013) Psychobiotics: a novel class of psychotropic. Biol Psychiatry 74(10):720\u2013726. https:\/\/doi.org\/10.1016\/j.biopsych.2013.05.001","journal-title":"Biol Psychiatry"},{"issue":"15","key":"1726_CR18","doi-asserted-by":"publisher","first-page":"8586","DOI":"10.3390\/ijms23158586","volume":"23","author":"S Duperrier","year":"2022","unstructured":"Duperrier S, Bortolozzi A, Sgambato V (2022) Increased expression of alpha, beta-, and gamma-synucleins in brainstem regions of a non-human primate model of Parkinson\u2019s Disease. Int J Mol Sci 23(15):8586. https:\/\/doi.org\/10.3390\/ijms23158586","journal-title":"Int J Mol Sci"},{"key":"1726_CR19","unstructured":"Enright BP, Huang Y, Kym PR, Lao Y, Lou X, Mackey SE, Mayer PT, Miller CP, Stella VJ, Voight EA, Inventors; AbbVie Inc, Assignee. Methods of Treating Parkinson\u2019s Disease. United States Patent US 11,091,507. 2021.\u201d https:\/\/patents.google.com\/patent\/US11091507B2\/en (September 22, 2024)."},{"key":"1726_CR20","doi-asserted-by":"publisher","first-page":"1145877","DOI":"10.3389\/fchem.2023.1145877","volume":"11","author":"P Esha","year":"2023","unstructured":"Esha P, Das L, Das AK, Dolui S, Saha S, Pal U, Mondal A et al (2023) Single point mutations at the S129 residue of \u03b1-synuclein and their effect on structure, aggregation, and neurotoxicity. FCHEM 11:1145877. https:\/\/doi.org\/10.3389\/fchem.2023.1145877","journal-title":"FCHEM"},{"key":"1726_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tifs.2019.09.004","volume":"93","author":"D Farias","year":"2019","unstructured":"Farias D, de Paulo F, de Ara\u00fajo F, Neri-Numa IA, Pastore GM (2019) Prebiotics: trends in food, health and technological applications. Trends Food Sci Technol 93:23\u201335. https:\/\/doi.org\/10.1016\/j.tifs.2019.09.004","journal-title":"Trends Food Sci Technol"},{"key":"1726_CR22","unstructured":"\u201cFariello R, Cattaneo C, Salvati P, Benatti L, Inventors; Newron Pharmaceuticals SpA, Assignee. Methods for Treatment of Parkinson\u2019s Disease. United States Patent US 8,283,380. 2012 Oct 9.\u201d https:\/\/patents.google.com\/patent\/US8283380B2\/en (September 22, 2024)."},{"key":"1726_CR23","doi-asserted-by":"publisher","first-page":"1151850","DOI":"10.3389\/fnagi.2023.1151850","volume":"15","author":"G Hey","year":"2023","unstructured":"Hey G, Nair N, Klann E, Gurrala A, Safarpour D, Mai V, RamirezZamora A, Vedam-Mai V (2023) Therapies for Parkinson\u2019s Disease and the gut microbiome: evidence for bidirectional connection. Front Aging Neurosci 15:1151850. https:\/\/doi.org\/10.3389\/fnagi.2023.1151850","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1726_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s13534019-00115-x","volume":"9","author":"N Hong","year":"2019","unstructured":"Hong N (2019) Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomed Eng Lett 9(3):359\u2013366. https:\/\/doi.org\/10.1007\/s13534019-00115-x","journal-title":"Biomed Eng Lett"},{"issue":"S3","key":"1726_CR25","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003) Oxidative stress in Parkinson\u2019s Disease. Ann Neurol 53(S3):S26-38. https:\/\/doi.org\/10.1002\/ana.10483","journal-title":"Ann Neurol"},{"key":"1726_CR101","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/bj3230539","volume":"323","author":"PH Jensen","year":"1997","unstructured":"Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R (1997) Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein\/NAC precursor that bind Abeta and NAC. Biochem J 323:539\u2013546. https:\/\/doi.org\/10.1042\/bj3230539","journal-title":"Biochem J"},{"key":"1726_CR26","doi-asserted-by":"publisher","first-page":"570658","DOI":"10.3389\/fcimb.2020.570658","volume":"10","author":"L Jing","year":"2020","unstructured":"Jing L, Fei Xu, Nie Z, Shao L (2020a) Gut microbiota approach\u2014a new strategy to treat Parkinson\u2019s Disease. Front Cell Infect Microbiol 10:570658. https:\/\/doi.org\/10.3389\/fcimb.2020.570658","journal-title":"Front Cell Infect Microbiol"},{"key":"1726_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","volume":"132","author":"T Jonathan","year":"2017","unstructured":"Jonathan T, Nitu B, Datieva V, Odin P, Antonini A (2017) DeviceAided treatment strategies in advanced Parkinson\u2019s Disease. Int Rev Neurobiol 132:453\u2013474. https:\/\/doi.org\/10.1016\/bs.irn.2017.03.001","journal-title":"Int Rev Neurobiol"},{"key":"1726_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29682","author":"DJ Kim","year":"2023","unstructured":"Kim DJ, Isidro-P\u00e9rez AL, Doering M, Llibre-Rodriguez JJ, Acosta I, Rodriguez AM et al (2023) Prevalence and incidence of Parkinson\u2019s Disease in Latin America: a meta-analysis. Mov Disord. https:\/\/doi.org\/10.1002\/mds.29682","journal-title":"Mov Disord"},{"issue":"4","key":"1726_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/medicina60040601","volume":"60","author":"L \u0136imse","year":"2024","unstructured":"\u0136imse L, Reinis A, Mi\u0137elsone-Jansone L, Gintere S, Kr\u016bmi\u0146a A (2024a) A narrative review of psychobiotics: probiotics that influence the gut-brain axis. Med Tradic 60(4):601. https:\/\/doi.org\/10.3390\/medicina60040601","journal-title":"Med Tradic"},{"issue":"4","key":"1726_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/medicina60040601","volume":"60","author":"L \u0136imse","year":"2024","unstructured":"\u0136imse L, Reinis A, Mi\u0137elsone-Jansone L, Gintere S, Kr\u016bmi\u0146a A (2024b) A narrative review of psychobiotics: probiotics that influence the gut-brain axis. Med 60(4):601. https:\/\/doi.org\/10.3390\/medicina60040601","journal-title":"Med"},{"key":"1726_CR100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA \u0136Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38\u201348. https:\/\/doi.org\/10.1038\/nrn3406","journal-title":"Nat Rev Neurosci"},{"key":"1726_CR31","doi-asserted-by":"publisher","first-page":"1028356","DOI":"10.3389\/fphar.2022.1028356","volume":"13","author":"K Latif","year":"2022","unstructured":"Latif K, Aman U, Anastasiia DS, Dmytro IB, Zakia R, Badrah SA, Mohamed AA, Ghulam MA (2022) Drug reprofiling history and potential therapies against Parkinson\u2019s Disease. Front Pharmacol 13:1028356","journal-title":"Front Pharmacol"},{"issue":"12","key":"1726_CR32","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.3390\/ijms23126643","volume":"23","author":"JE Lee","year":"2022","unstructured":"Lee JE, Walton D, O\u2019Connor CP, Wammes M, Burton JP, Osuch EA (2022) Drugs, Guts, Brains, but Not Rock and Roll: The Need to Consider the Role of Gut Microbiota in Contemporary Mental Health and Wellness of Emerging Adults. Int J Mol Sci 23(12):6643. https:\/\/doi.org\/10.3390\/ijms23126643","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1726_CR33","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s11427-016-9001-4","volume":"60","author":"W Li","year":"2017","unstructured":"Li W, Wu X, Hu X, Wang T, Liang S, Duan Y et al (2017) Structural changes of gut microbiota in Parkinson\u2019s disease and its correlation with clinical features. Sci China Life Sci 60(11):1223\u20131233. https:\/\/doi.org\/10.1007\/s11427-016-9001-4","journal-title":"Sci China Life Sci"},{"key":"1726_CR34","doi-asserted-by":"publisher","unstructured":"Liu, Jing, Fei Xu, Zhiyan Nie, and Lei Shao. 2020. \u201cGut Microbiota Approach\u2014A New Strategy to Treat Parkinson\u2019s Disease.\u201d Fcimb. 10. https:\/\/doi.org\/10.3389\/fcimb.2020.570658.","DOI":"10.3389\/fcimb.2020.570658"},{"issue":"5","key":"1726_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3111\/13696998.2011.598201","volume":"14","author":"J Lowin","year":"2011","unstructured":"Lowin J, Annika Bergman K, Chaudhuri R, Findley LJ, Roeder C, Schifflers M, Wood E, Morris S (2011) A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s Disease in the UK. J Med Econ 14(5):584\u2013593. https:\/\/doi.org\/10.3111\/13696998.2011.598201","journal-title":"J Med Econ"},{"key":"1726_CR36","doi-asserted-by":"publisher","first-page":"105397","DOI":"10.1016\/j.jff.2022.105397","volume":"100","author":"S Mehrabani","year":"2023","unstructured":"Mehrabani S, Khorvash F, Heidari Z, Tajabadi-Ebrahimi M, Amani R (2023) The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with parkinson\u2019s disease: a double-blind, placebo-controlled, randomized controlled trial. J Funct Foods 100:105397. https:\/\/doi.org\/10.1016\/j.jff.2022.105397","journal-title":"J Funct Foods"},{"issue":"5","key":"1726_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-024-01073-4","volume":"38","author":"E Menozzi","year":"2024","unstructured":"Menozzi E, Schapira AHV (2024) The gut microbiota in Parkinson Disease: interactions with drugs and potential for therapeutic applications. CNS Drugs 38(5):315\u2013331. https:\/\/doi.org\/10.1007\/s40263-024-01073-4","journal-title":"CNS Drugs"},{"key":"1726_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10567-w","author":"V Metta","year":"2021","unstructured":"Metta V, Leta V, Mrudula KR, Prashanth LK, Goyal V, Borgohain R et al (2021) Gastrointestinal dysfunction in Parkinson\u2019s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10567-w","journal-title":"J Neurol"},{"issue":"2","key":"1726_CR39","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/ijms25021294","volume":"25","author":"A Montalb\u00e1n-Rodr\u00edguez","year":"2024","unstructured":"Montalb\u00e1n-Rodr\u00edguez A, Abalo R, L\u00f3pez-G\u00f3mez L (2024) From the gut to the brain: the role of enteric glial cells and their involvement in the pathogenesis of Parkinson\u2019s Disease. Int J Mol Sci 25(2):1294. https:\/\/doi.org\/10.3390\/ijms25021294","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1726_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMct1208070","volume":"367","author":"MS Okun","year":"2012","unstructured":"Okun MS (2012) Deep-brain stimulation for Parkinson\u2019s Disease. NEJM 367(16):1529\u20131538. https:\/\/doi.org\/10.1056\/NEJMct1208070","journal-title":"NEJM"},{"issue":"4","key":"1726_CR41","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/acschembio.4c00095","volume":"19","author":"L Ortiz de Ora","year":"2024","unstructured":"Ortiz de Ora L, Balsamo JM, Uyeda KS, Bess EN (2024) Discovery of a Gut Bacterial Metabolic Pathway That Drives \u03b1-Synuclein Aggregation. ACS Chem Biol 19(4):1011\u20131021. https:\/\/doi.org\/10.1021\/acschembio.4c00095","journal-title":"ACS Chem Biol"},{"key":"1726_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","volume":"29","author":"E P\u00e5lhagen Sven","year":"2016","unstructured":"P\u00e5lhagen Sven E, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, Dizdar N et al (2016) Levodopa-Carbidopa Intestinal Gel (LCIG) Treatment in Routine Care of Patients with Advanced Parkinson\u2019s Disease: An Open-Label Prospective Observational Study of Effectiveness, Tolerability and Healthcare Costs. PRDIFO 29:17\u201323. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.06.002","journal-title":"PRDIFO"},{"issue":"3","key":"1726_CR43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"C Paolo","year":"2023","unstructured":"Paolo C, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cddis 14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cddis"},{"issue":"1","key":"1726_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41531-024-00779-y","volume":"10","author":"GM Pereira","year":"2024","unstructured":"Pereira GM, Teixeira-Dos-Santos D, Soares NM, Marconi GA, Friedrich DC, Awad PS et al (2024) A systematic review and meta-analysis of the prevalence of Parkinson\u2019s disease in lower to upper-middle-income countries. Npj Parkinsons Dis 10(1):181","journal-title":"Npj Parkinsons Dis"},{"issue":"6","key":"1726_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10517-017-3700-7","volume":"162","author":"VA Petrov","year":"2017","unstructured":"Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB et al (2017) Analysis of Gut Microbiota in Patients with Parkinson\u2019s Disease. Bull Exp Biol Med 162(6):734\u2013737. https:\/\/doi.org\/10.1007\/s10517-017-3700-7","journal-title":"Bull Exp Biol Med"},{"key":"1726_CR46","doi-asserted-by":"publisher","first-page":"00299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"FC Rutherford","year":"2019","unstructured":"Rutherford FC, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting alpha-synuclein as a therapy for Parkinson\u2019s Disease. FNMOL 12:00299. https:\/\/doi.org\/10.3389\/fnmol.2019.00299","journal-title":"FNMOL"},{"issue":"3","key":"1726_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD130186","volume":"3","author":"D Salat","year":"2013","unstructured":"Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson\u2019s Disease: current status and new developments. JPD 3(3):255\u2013269. https:\/\/doi.org\/10.3233\/JPD130186","journal-title":"JPD"},{"issue":"1","key":"1726_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41531-019-0100-x","volume":"5","author":"W Severin","year":"2019","unstructured":"Severin W, Schwiertz A, Unger MM, Becker A, Fa\u00dfbender K, Ratering S, Kohl M et al (2019) Effect of Parkinson\u2019s Disease and Related Medications on the Composition of the Fecal Bacterial Microbiota. Npj Parkinson\u2019s Dis 5(1):28. https:\/\/doi.org\/10.1038\/s41531-019-0100-x","journal-title":"Npj Parkinson\u2019s Dis"},{"issue":"1","key":"1726_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36(1):1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002","journal-title":"Clin Geriatr Med"},{"key":"1726_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fphar.2012.00059","volume":"3","author":"CE Stafstrom","year":"2012","unstructured":"Stafstrom CE, Rho JM (2012) The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 3:59. https:\/\/doi.org\/10.3389\/fphar.2012.00059","journal-title":"Front Pharmacol"},{"key":"1726_CR51","doi-asserted-by":"publisher","first-page":"862","DOI":"10.12688\/f1000research.25634.1","volume":"9","author":"TB Stoker","year":"2020","unstructured":"Stoker TB, Barker RA (2020) Recent developments in the treatment of Parkinson\u2019s Disease. F1000Res 9:862","journal-title":"F1000Res"},{"issue":"1","key":"1726_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-022-00327-6","volume":"8","author":"H Sun","year":"2022","unstructured":"Sun H, Zhao F, Liu Y, Ma T, Jin H, Quan K, Leng B et al (2022) Probiotics synergized with conventional regimen in managing Parkinson\u2019s Disease. Npj Parkinson\u2019s Dis 8(1):62. https:\/\/doi.org\/10.1038\/s41531-022-00327-6","journal-title":"Npj Parkinson\u2019s Dis"},{"issue":"4","key":"1726_CR53","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jgh3.12450","volume":"5","author":"AH Tan","year":"2021","unstructured":"Tan AH, Hor JW, Chong CW, Lim S-Y (2021) Probiotics for Parkinson\u2019s Disease: current evidence and future directions. JGH Open 5(4):414\u2013419. https:\/\/doi.org\/10.1002\/jgh3.12450","journal-title":"JGH Open"},{"issue":"1","key":"1726_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41531-024-00778-z","volume":"10","author":"C Towns","year":"2024","unstructured":"Towns C, Fang ZH, Tan MM, Jasaityte S, Schmaderer TM, Stafford EJ et al (2024) Parkinson\u2019s families project: a UK-wide study of early onset and familial Parkinson\u2019s disease. Npj Parkinsons Dis 10(1):188. https:\/\/doi.org\/10.1038\/s41531-024-00778-z","journal-title":"Npj Parkinsons Dis"},{"issue":"7","key":"1726_CR55","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/jcm9072159","volume":"9","author":"RM Tucker","year":"2020","unstructured":"Tucker RM, Augustin AD, Hayee BH, Bjarnason I, Taylor D, Weller C et al (2020) Role of helicobacters in neuropsychiatric disease: a systematic review in idiopathic parkinsonism. J Clin Med 9(7):2159. https:\/\/doi.org\/10.3390\/jcm9072159","journal-title":"J Clin Med"},{"key":"1726_CR56","doi-asserted-by":"publisher","first-page":"1348279","DOI":"10.3389\/fcimb.2024.1348279","volume":"14","author":"MN Uddin","year":"2024","unstructured":"Uddin MN, Islam MM, Hong ST, Chung HJ (2024) Dysbiosis of the gut microbiota and its effect on \u03b1-synuclein and prion protein misfolding: consequences for neurodegeneration. Front Cell Infect Microbiol 14:1348279. https:\/\/doi.org\/10.3389\/fcimb.2024.1348279","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1726_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-230366","volume":"14","author":"I van der Berg","year":"2024","unstructured":"van der Berg I, Schootemeijer S, Overbeek K, Bloem BR, de Vries NM (2024) Dietary interventions in Parkinson\u2019s Disease. J Parkinsons Dis 14(1):1\u201316. https:\/\/doi.org\/10.3233\/JPD-230366","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1726_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S (2019) Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s Disease. Nat Commun 10(1):310. https:\/\/doi.org\/10.1038\/s41467-019-08294-y","journal-title":"Nat Commun"},{"issue":"4","key":"1726_CR59","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1021\/acs.jafc.1c07711","volume":"70","author":"L Wang","year":"2022","unstructured":"Wang L, Zhao Z, Zhao L, Zhao Y, Yang Ge, Wang C, Gao L, Niu C, Li S (2022) Lactobacillus Plantarum DP189 Reduces \u03b1-SYN aggravation in MPTP-Induced Parkinson\u2019s Disease mice via regulating oxidative damage, inflammation, and gut microbiota disorder. J Agric Food Chem 70(4):1163\u20131173. https:\/\/doi.org\/10.1021\/acs.jafc.1c07711","journal-title":"J Agric Food Chem"},{"issue":"1","key":"1726_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced parkinson disease: a randomized controlled trial. JAMA 301(1):63. https:\/\/doi.org\/10.1001\/jama.2008.929","journal-title":"JAMA"},{"issue":"1","key":"1726_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/nu11010169","volume":"11","author":"D W\u0142odarek","year":"2019","unstructured":"W\u0142odarek D (2019) Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer\u2019s Disease and Parkinson\u2019s Disease). Nutr 11(1):169. https:\/\/doi.org\/10.3390\/nu11010169","journal-title":"Nutr"},{"key":"1726_CR62","unstructured":"World Health Organisation. Launch of WHO\u2019s Parkinson Disease Technical Brief [Internet]. www.who.int. 2022. Available from: https:\/\/www.who.int\/news\/item\/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief"},{"issue":"1","key":"1726_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/biology12010093","volume":"12","author":"G Xiromerisiou","year":"2023","unstructured":"Xiromerisiou G, Marogianni C, Androutsopoulou A, Ntavaroukas P, Mysiris D, Papoutsopoulou S (2023) Parkinson\u2019s Disease, It Takes Guts: The Correlation between Intestinal Microbiome and Cytokine Network with Neurodegeneration. Biology 12(1):93. https:\/\/doi.org\/10.3390\/biology12010093","journal-title":"Biology"},{"issue":"1","key":"1726_CR64","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40035-023-00392-8","volume":"12","author":"Z Xuxiang","year":"2023","unstructured":"Xuxiang Z, Tang B, Guo J (2023) Parkinson\u2019s Disease and Gut microbiota: from clinical to mechanistic and therapeutic studies. Transl Neurodegener 12(1):59","journal-title":"Transl Neurodegener"},{"issue":"4","key":"1726_CR65","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3233\/JPD-212707","volume":"11","author":"N Yemula","year":"2021","unstructured":"Yemula N, Dietrich C, Dostal V, Hornberger M (2021) Parkinson\u2019s Disease and the Gut: symptoms, nutrition, and microbiota. J Parkins Dis 11(4):1491\u20131505. https:\/\/doi.org\/10.3233\/JPD-212707","journal-title":"J Parkins Dis"},{"issue":"5","key":"1726_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s13238-018-0541-8","volume":"9","author":"F Zhang","year":"2018","unstructured":"Zhang F, Cui B, He X, Nie Y, Kaichun Wu, Fan D (2018) Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell 9(5):462\u2013473. https:\/\/doi.org\/10.1007\/s13238-018-0541-8","journal-title":"Protein Cell"},{"issue":"6","key":"1726_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.31083\/j.jin2206157","volume":"22","author":"W Zhang","year":"2023","unstructured":"Zhang W, Ye Y, Song J, Sang T, Xia T, Xie L, Qiu X, Zeng Q, Luo X (2023) Research progress of microbiota-gut-brain axis in Parkinson\u2019s Disease. J Integr Neurosci 22(6):157","journal-title":"J Integr Neurosci"},{"key":"1726_CR68","doi-asserted-by":"publisher","first-page":"937555","DOI":"10.3389\/FIMMU.2022.937555","volume":"13","author":"M Zhu","year":"2022","unstructured":"Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, Chen F, Ling Z (2022) Gut microbiota: a novel therapeutic target for Parkinson\u2019s Disease. Front Immunol 13:937555. https:\/\/doi.org\/10.3389\/FIMMU.2022.937555","journal-title":"Front Immunol"},{"issue":"7","key":"1726_CR69","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","volume":"5","author":"J Zhu","year":"2024","unstructured":"Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao D et al (2024) Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis. The Lancet Health Longev 5(7):e464\u2013e479. https:\/\/doi.org\/10.1016\/S2666-7568(24)00094-1","journal-title":"The Lancet Health Longev"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01726-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:07:00Z","timestamp":1750226820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01726-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01726-w","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}